News about Global Pharma

Shilpa Medicare Targets US Approval for Oeris After Successful Phase Three Trial

Shilpa Medicare seeks licensing partners for extended-release ondansetron injection to treat chemotherapy-induced nausea and vomiting.

Global Pharma | 09/01/2026 | By News Bureau |  321

PAI Pharma, Olympus Partners Acquire Nivagen to Expand US Sterile Injectable Manufacturing

Deal strengthens domestic pharmaceutical production with advanced aseptic facility and robust ready-to-use injectable pipeline.

Global Pharma | 09/01/2026 | By News Bureau |  597

SPARC Announces Major Workforce Reduction, Shifts to Hybrid R&D Model

Sun Pharma Advanced Research Company Ltd. (SPARC) has announced plans to reduce its workforce by around 40% as part of a broader restructuring aimed at streamlining operations and optimising costs. The impact will be most pronounced in the United States, where more than 80% of employees are expected to be laid off, according to company disclosures.

Global Pharma | 09/01/2026 | By Darshana |  787

GSK Secures EU Approval for Simplified Shingrix Presentation in Prefilled Syringe

GSK plc announced that the European Commission (EC) has approved a new prefilled syringe presentation of Shingrix, the company’s recombinant zoster vaccine (RZV), aimed at simplifying administration for healthcare professionals across the European Union.

Global Pharma | 08/01/2026 | By Darshana |  243

Amgen Acquires UK- based Dark Blue Therapeutics in 840M USD Deal

Amgen’s acquisition of Dark Blue Therapeutics, adds a first-in-class protein degrader programme targeting MLLT1/3-driven acute myeloid leukemia to strengthen its early-stage oncology pipeline.<br />

Global Pharma | 07/01/2026 | By News Bureau |  179

Japan Approves Exdensur for Severe Asthma and Nasal Polyps

Japan has approved Exdensur (depemokimab) for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), marking the first ultra-long-acting biologic in the country, with approval supported by phase-III SWIFT and ANCHOR trial data demonstrating sustained efficacy with twice-yearly dosing.

Global Pharma | 07/01/2026 | By News Bureau |  360

China Approves Nucala from GSK for Adult COPD Treatment

China has approved Nucala (mepolizumab) for adult COPD, supported by phase-III MATINEE and METREX trials showing reduced exacerbations in patients with blood eosinophil counts from 150 cells/µL.

Global Pharma | 06/01/2026 | By News Bureau |  448

MHRA Approves New mRNA COVID-19 Booster

The new approved vaccine, Zapomeran (Kostaive) is cleared for adults aged 18 years and above.

Global Pharma | 05/01/2026 | By News Bureau |  330

Novo Nordisk Secures Key China Patent Win for Semaglutide

The Supreme People’s Court of China has delivered a favourable ruling on the intellectual property rights related to the semaglutide compound patent, upholding an earlier decision by the Beijing Intellectual Property Court that confirmed the patent’s validity.

Global Pharma | 04/01/2026 | By Darshana |  498

Mabwell Adalimumab Biosimilar Wins Marketing Approval in Indonesia

Mabwell’s adalimumab biosimilar 9MW0113, co-developed with Junshi Biosciences, has received marketing approval from Indonesia’s BPOM, becoming the first China-developed adalimumab biosimilar to secure such approval, as the company advances global expansion with partnerships in over 10 countries.

Global Pharma | 01/01/2026 | By News Bureau |  189